0.05Open0.05Pre Close0 Volume3.07K Open Interest10.00Strike Price0.00Turnover574.99%IV1027.95%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1333Delta0.1786Gamma17.83Leverage Ratio-0.0063Theta0.0000Rho2.38Eff Leverage0.0005Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet